ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.12 | 0.28 | -0.40 | -0.00 |
| FCF Yield | 1.27% | -11.39% | -11.82% | -9.16% |
| EV / EBITDA | -338.05 | -6.69 | -3.72 | -7.34 |
| Quality | ||||
| ROIC | -0.91% | -29.20% | -12.85% | -34.20% |
| Gross Margin | 98.90% | 100.00% | 100.00% | 96.13% |
| Cash Conversion Ratio | 1.69 | 1.09 | 1.16 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 307.65% | -82.40% | -58.06% | – |
| Free Cash Flow Growth | 121.85% | -47.58% | -128.64% | -316.04% |
| Safety | ||||
| Net Debt / EBITDA | 17.66 | 1.05 | 5.97 | 2.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -183.53 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,702.68 | 9,672.50 | 279.85 | -3,060.45 |